Literature DB >> 22307876

Utilization of general and specialized cardiac care by people with schizophrenia.

Lauren C Bresee1, Sumit R Majumdar, Scott B Patten, Jeffrey A Johnson.   

Abstract

OBJECTIVE: Whether access to primary and specialist care has an impact on treatment for people with schizophrenia and comorbid cardiac disease is unclear. The objective of this study was to compare use of general health care and specialized cardiac care by people with schizophrenia and by the rest of the population.
METHODS: A population-based period-prevalence study was conducted and included adults (N=2,310,391) in Alberta, Canada, by using administrative databases. People with schizophrenia were identified based on billing codes; all others served as the comparator cohort. Multivariable logistic regression analyses were conducted to compare claims for general (general practitioner visits) health care, urgent and emergent (emergency department visits and hospitalizations) health services, and specialized cardiac (cardiologist visits, revascularization) care.
RESULTS: Individuals with schizophrenia (N=28,755) had a higher prevalence of coronary artery disease than those without schizophrenia (N=2,281,636) (20% versus 14%) and were more likely than those without schizophrenia to visit a general practitioner more than four times per year (76% versus 47%; adjusted odds ratio [AOR]=3.60, 95% confidence interval [CI]=3.49-3.71). In contrast, individuals with schizophrenia and coronary artery disease were less likely to visit a cardiologist (50% versus 59%; AOR=. 76, 95% CI=.72-.80) or undergo coronary revascularization (6% versus 12%; AOR=. 55, 95% CI=.49-.61).
CONCLUSIONS: In this large population-based study, individuals with schizophrenia were less likely to visit cardiologists or undergo revascularization than were people without schizophrenia. Opportunities exist for better assessment and management of cardiovascular disease and risk factors among people with schizophrenia.

Entities:  

Mesh:

Year:  2012        PMID: 22307876     DOI: 10.1176/appi.ps.201000363

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  10 in total

1.  On Adjusting for Life's Confounding.

Authors:  Steve Kisely
Journal:  Can J Psychiatry       Date:  2016-07-19       Impact factor: 4.356

2.  Emergency department utilization among Medicaid beneficiaries with schizophrenia and diabetes: the consequences of increasing medical complexity.

Authors:  Ruth S Shim; Benjamin G Druss; Shun Zhang; Giyeon Kim; Adesoji Oderinde; Sosunmolu Shoyinka; George Rust
Journal:  Schizophr Res       Date:  2013-12-28       Impact factor: 4.939

3.  Severe mental illness and health service utilisation for nonpsychiatric medical disorders: A systematic review and meta-analysis.

Authors:  Amy Ronaldson; Lotte Elton; Simone Jayakumar; Anna Jieman; Kristoffer Halvorsrud; Kamaldeep Bhui
Journal:  PLoS Med       Date:  2020-09-14       Impact factor: 11.069

4.  Mortality, Revascularization, and Cardioprotective Pharmacotherapy After Acute Coronary Syndrome in Patients With Psychotic Disorders: A Population-Based Cohort Study.

Authors:  Wing Chung Chang; Joe Kwun Nam Chan; Corine Sau Man Wong; JoJo Siu Han Hai; Philip Chi Fai Or; Eric Yu Hai Chen
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

5.  Diagnostic tests and treatment procedures performed prior to cardiovascular death in individuals with severe mental illness.

Authors:  I H Heiberg; R Nesvåg; L Balteskard; J G Bramness; C M Hultman; Ø Naess; T Reichborn-Kjennerud; E Ystrom; B K Jacobsen; A Høye
Journal:  Acta Psychiatr Scand       Date:  2020-02-29       Impact factor: 6.392

6.  Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study.

Authors:  Silvana Galderisi; Marc De Hert; Stefano Del Prato; Andrea Fagiolini; Philip Gorwood; Stefan Leucht; Aldo Pietro Maggioni; Armida Mucci; Celso Arango
Journal:  Eur Psychiatry       Date:  2021-01-08       Impact factor: 5.361

Review 7.  Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction.

Authors:  Kah Kheng Goh; Cynthia Yi-An Chen; Tzu-Hua Wu; Chun-Hsin Chen; Mong-Liang Lu
Journal:  Int J Mol Sci       Date:  2022-06-25       Impact factor: 6.208

8.  Antipsychotic drugs and risks of myocardial infarction: a self-controlled case series study.

Authors:  Ruth Brauer; Liam Smeeth; Karim Anaya-Izquierdo; Adam Timmis; Spiros C Denaxas; C Paddy Farrington; Heather Whitaker; Harry Hemingway; Ian Douglas
Journal:  Eur Heart J       Date:  2014-07-08       Impact factor: 29.983

9.  Detection of subclinical atherosclerosis and diastolic dysfunction in patients with schizophrenia.

Authors:  Cüneyt Unsal; Mustafa Oran; Hande Oktay Tureli; Seref Alpsoy; Sema Yeşilyurt; Mehtap Arslan; Birol Topcu; Osman Karakaya; Erhan Kurt
Journal:  Neuropsychiatr Dis Treat       Date:  2013-10-08       Impact factor: 2.570

10.  Factors associated with visits to general practitioners in patients with schizophrenia in Malaga.

Authors:  M C Castillejos; C Martín-Pérez; F Mayoral-Cleries; A Bordallo-Aragón; J Sepúlveda-Muñoz; B Moreno-Küstner
Journal:  BMC Fam Pract       Date:  2018-11-28       Impact factor: 2.497

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.